Clinical Trial Update: A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation [Phase 1]

View source ↗

Summary

This clinical trial entry reports a Phase I study of IX001 TCR-T Injection for advanced pancreatic cancer with KRAS G12V mutation; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• IX001 TCR-T Injection (TCR-T cell therapy targeting KRAS G12V mutation)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Pancreatic Cancer | Phase 1 | Status: RECRUITING